• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Xanthines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyrimidines Purines and purine derivatives Xanthines

1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl): A Comprehensive Overview

1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl) (CAS No. 31542-68-4) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound belongs to the purine family and is characterized by its unique structural features and potential biological activities. In this comprehensive overview, we will delve into the chemical structure, synthesis methods, biological properties, and recent research advancements of this compound.

Chemical Structure and Properties

The molecular formula of 1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl) is C₂₀H₂₀N₄O₂, with a molecular weight of approximately 344.40 g/mol. The compound features a central purine core with two phenylmethyl (benzyl) groups attached at the 1 and 3 positions. The presence of these benzyl groups significantly influences the compound's solubility and stability in various solvents. Additionally, the 2,6-diketone functionality imparts unique reactivity and potential for forming hydrogen bonds, which are crucial for its biological interactions.

Synthesis Methods

The synthesis of 1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl) has been explored through various routes. One common method involves the condensation of a suitable purine derivative with benzyl halides in the presence of a base. For instance, the reaction of 2,6-dichloropurine with benzyl bromide in dimethylformamide (DMF) and potassium carbonate can yield the desired product in moderate to good yields. Another approach involves the palladium-catalyzed coupling reactions of appropriately substituted purines with benzyl boronic acids or chlorides.

Biological Activities

1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl) has been studied for its potential biological activities, particularly in the context of enzyme inhibition and cellular signaling. Recent research has shown that this compound exhibits potent inhibitory activity against certain kinases and phosphodiesterases (PDEs), which are key enzymes involved in signal transduction pathways. For example, it has been reported to inhibit PDE4 with an IC₅₀ value in the low micromolar range. This property makes it a promising lead compound for the development of anti-inflammatory and anti-cancer drugs.

Pharmacological Applications

The pharmacological applications of 1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl) are diverse and span multiple therapeutic areas. In preclinical studies, it has demonstrated efficacy in reducing inflammation and preventing tumor growth. Specifically, its ability to modulate PDE4 activity has been linked to reduced levels of pro-inflammatory cytokines such as TNF-α and IL-6. Moreover, its anti-proliferative effects on cancer cells have been attributed to its ability to induce apoptosis and inhibit cell cycle progression.

Clinical Trials and Future Prospects

The promising preclinical results have led to increased interest in advancing 1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl) into clinical trials. Several Phase I trials are currently underway to evaluate its safety and efficacy in treating inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Additionally, early-stage clinical trials are exploring its potential as an adjunct therapy for cancer treatment.

Conclusion

In summary, 1H-Purine-2,6-dione, 3,9-dihydro-1,3-bis(phenylmethyl) (CAS No. 31542-68-4) is a multifaceted compound with significant potential in medicinal chemistry and pharmaceutical research. Its unique chemical structure and biological activities make it an attractive candidate for further development as a therapeutic agent. Ongoing research and clinical trials will continue to elucidate its full therapeutic potential and pave the way for new treatments in various medical conditions.

• 2850-36-4(1,3-Dibutylxanthine)
• 31542-62-8(1,3-Dipropylxanthine)
• 75922-48-4(1,3-Diethyl-8-phenylxanthine)
• 57000-13-2(1H-Purine-2,6-dione,3,9-dihydro-1,3-dimethyl-8-[(phenylmethyl)amino]-)
• 19844-93-0(3-benzyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione)
• 961-45-5(1,3-Dimethyl-8-phenylxanthine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)